Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports

Anti-Cancer Drugs

Volumn 22, Issue 6, 2011, Pages 563-568

  Yoshii, Noritoshi ^a   Suzuki, Tadamichi ^a   Nagashima, Masaki ^a   Kon, Akira ^a   Kakihata, Koji ^a   Gemma, Akihiko ^b  

^a DAIICHI SANKYO CO   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

diffuse alveolar damage; interstitial lung disease; irinotecan

Indexed keywords

FLUOROPYRIMIDINE; GEMCITABINE; IRINOTECAN; PLATINUM; STEROID; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGNOSIS; STEROID THERAPY; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NEOPLASMS; PNEUMONIA; PRODUCT SURVEILLANCE, POSTMARKETING; PULMONARY ALVEOLI; STEROIDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79958295071     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283473f28     Document Type: Article

References (31)

1. Yamada M, Kudoh S, Hirata K, Nakajima T, Yoshikawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 1998; 34:71-75.
2. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10:1225-1229.
3. Oshita F, Noda K, Nishiwaki Y, Fujita A, Kurita Y, Nakabayashi Y, et al. Phase study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1997; 15:304-309. (Pubitemid 27020588)
4. Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol 2005; 15:173-179. (Pubitemid 40983484)
5. Muller NL, White DA, Jiang H, Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 2004; 91 (Suppl 2): S24-S30. (Pubitemid 39334844)
6. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008; 133:528-538. (Pubitemid 351272414)
7. AstraZeneca and Iressa Expert Committee. Final report on interstitial lung disease (ILD) related to gefetinib (Iressa Tablet 250). Tokyo Japan: AstraZeneca Japan; 2003.
8. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer, a cohort and nested case-control study. Am J Respir Crit Care Med 2008; 177:1348-1357. (Pubitemid 351860912)
9. Gemma A. Drug-induced interstitial lung disease associated with moleculartargeted anticancer agents. J Nippon Med Sch 2009; 76:4-8.
10. Makris D, Scherppereel A, Copin MC, Colin G, Brun L, Laffite JJ, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007; 7:150.
11. Liu V, White DA, Zakowski MF, Travis W, Kris MG, Grinsberg MS, et al. Pulmonary toxicity associated with erlotinib. Chest 2007; 132:1042-1044.
12. Camas P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004; 91 (Suppl 2):S18-S23. (Pubitemid 39331428)
13. Cooper JA Jr,White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis 1986; 133:321-340. (Pubitemid 16123932)
14. Cooper JA Jr,White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: cytotoxic drugs. Am Rev Respir Dis 1986; 133:488-505. (Pubitemid 16126287)
15. Erasmus JJ, McAdams HP, Rossi SE. High-resolution CT of drug-induced lung disease. Radiol Clin North Am 2002; 40:61-72. (Pubitemid 34074135)
16. Madarnas Y, Webster P, Shorter AM, Bjarnason GA. Irinotecan-associated pulmonary toxicity. Anticancer Drugs 2000; 11:709-713.
17. Michielin O, Udry E, Périard D, Matzinger O, Lobrinus JA, Stupp R. Irinotecan-induced interstitial pneumonia. Lancet Oncol 2004; 5:322-324. (Pubitemid 38541585)
18. Takatani K, Miyazaki E, Nureki S, Ando M, Ueno T, Okubo T, et al. High-resolution computed tomography patterns and immunopathogenetic findings in drug-induced pneumonitis. Respir Med 2008; 102:892-898.
19. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Muller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002; 57:292-299. (Pubitemid 36503366)
20. Fraser RS, Mü ller NL, Colman N, Pare PD. Pulmonary disease caused by toxins, drugs, and irradiation. In: Fraser RS, Mü ller NL, Colman N, Pare PD, editor. Fraser and Pare's diagnosis of diseases of the chest. Philaderphia: WB Saunders; 1999. pp. 2517-2592.
21. Inoue K, Hiraoka N, Kasamatsu Y, Kawahito Y, Yoshioka K, Yokoo A. A case of irinotecan-induced pneumonitis. Jpn J Lung Cancer 2000; 40:219-221. (Pubitemid 30637410)
22. Maitland ML, Wilcox R, Hogarth DK, Desai AA, Caligiuri P, Abrahams C, et al. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer 2006; 54:243-245. (Pubitemid 44764922)
23. Ohnishi H, Yokoyama A, Yasuhara Y,Watanabe A, Naka T, Hamada H, et al. Circulating KL-6 levels in patients with drug-induced pneumonitis. Thorax 2003; 58:872-875. (Pubitemid 37239235)
24. Rossi SE, Erasmus JJ, MacAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000; 20:1245-1259.
25. Muller NL, Naidich DP. Disease characterized primarily by linear and reticular opacities. In: Webb WR, Muller NL, Nadich DP, editors. High-resolution CT of the lung. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 193-257.
26. Nakajima M, Kawahara Y, Yoshida K, Miyashita N, Niki Y, Matsushima T, et al. Serum KL-6 as a possible marker for amiodarone-induced pulmonary toxicity. Internal Med 2000; 39:1097-1100. (Pubitemid 32052325)
27. Daiichi Sankyo Company Limited. Topotecin package insert. Tokyo: Daiichi Sankyo Company Limited; 2009.
28. Naito Y, Tsuchiya S, Ishihara S, Minato K, Shitara Y, Takise A, et al. Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease. Am J Clin Oncol 2008; 31:340-344.
29. Niho S, Goto K, Yoh K, Kim YH, Ohmatsu H, Kubota K, et al. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. Jpn J Clin Oncol 2006; 36:269-273. (Pubitemid 43997330)
30. Koo LC, Clark JA, Quesenberry CP, Higenbottam T, Nyberg F,Wilf MK, et al. National differences in reporting 'pneumonia'and 'pneumonia interstitial': an analysis of the WHO international drug monitoring database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf 2005; 14:775-787. (Pubitemid 41684470)
31. Pfizer. CAMPTOSAR prescribing information. New York: Pfizer; 2009.